Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis

Whether the intensive administration of folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) alone or combined with target therapy as first-line treatment could improve the prognosis of metastatic colorectal cancer (mCRC) patients is controversial. PubMed, the Cochrane Collaboration...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mingyi, Yu, Ping, Hernick Davin, Dengue Bilibili, Li, Yanrong, Wang, Yuanhe, Fu, Lingyu, Zhang, Jingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617509/
https://www.ncbi.nlm.nih.gov/pubmed/28977949
http://dx.doi.org/10.18632/oncotarget.17725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617509/
https://www.ncbi.nlm.nih.gov/pubmed/28977949
http://dx.doi.org/10.18632/oncotarget.17725

Ejemplares similares